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S U M M A R Y
Objectives: The prevalence and clinical signiﬁcance of persistent candidemia among neonates are poorly
understood. This study aimed to describe the rate and the clinical relevance of persistent candidemia
over a 4-year period in Kuwait.
Methods: A retrospective chart review of infants admitted to the Neonatal Care Unit of the Maternity
Hospital in Kuwait between January 2007 and December 2010, who had a positive blood culture for
Candida species, was conducted. Persistent candidemia was deﬁned as the isolation of the same Candida
species more than 6 days after the initiation of antifungal therapy, or death due to candidemia within 6
days of antifungal treatment. Stepwise logistic regression was used to investigate factors associated with
persistent candidemia.
Results: Of 89 neonates with a Candida infection, 54 (60.7%, 95% conﬁdence interval 49.7–70.9%) had
persistent candidemia. The case-fatality rate was 54% among those with persistent candidemia and 3%
among those with non-persistent candidemia (p < 0.001). Neonates with persistent candidemia were
more likely to be female, have a central vascular catheter at diagnosis, and have a low platelet count. All
isolated Candida species were susceptible to antifungal agents.
Conclusions: Persistent candidemia is common among neonates with a Candida infection and is
associated with an increased risk of mortality. Drug resistance is unlikely to explain the persistent
candidemia; host-related factors seem to be more important and hence could be used to identify those at
risk in order to institute appropriate preventive and treatment measures.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Candida species are the leading cause of invasive fungal
infections in neonatal intensive care units and are the third most
common blood culture isolates in late-onset neonatal sepsis
(LOS).1,2 It is estimated that Candida infections contribute to nearly
2.4% of early-onset neonatal sepsis (EOS) and 10–12% of LOS.1,3 In a
5-year prospective study in Kuwait, Candida spp accounted for 4.6%
of EOS and approximately 11% of LOS.4,5 Several factors have
contributed to the current increase in the incidence of neonatal
Candida infections, including the global increase in prematurity6
and the increased rate of survival of premature babies, in addition
to factors related to their management, such as prolonged
endotracheal intubation, central vascular catheters (CVC), paren-
teral nutrition, and the use of broad-spectrum antibiotics. Neonatal
candidiasis causes signiﬁcant mortality and morbidity, with a case-* Corresponding author. Tel.: +965 25319920; fax: +965 25338940.
E-mail address: m.hammoud@hsc.edu.kw (M.S. Hammoud).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.11.020fatality rate between 15% and 60%; very low birth weight (VLBW)
infants (<1000 g) experience the highest mortality.2,7–10 In a
recent study from Kuwait, the case-fatality rate for Candida species
in LOS was 22%, signiﬁcantly higher than the case-fatality rate of
Gram-negative bacillary infections, or any other type of infection.5
Unlike bacterial infections in which persistent positive blood
cultures after the initiation of antimicrobial therapy indicate a
worse clinical outcome, Candida species take some time to clear
from the blood stream.7 It is uncertain whether persistent
candidemia represents treatment failure resulting in a poor
clinical outcome, or is part of the natural history of candidemia
in a responding patient. Only a few studies have investigated the
rate and the clinical signiﬁcance of persistent candidemia in
neonatal care units and their ﬁndings remain controversial.11–14
While some studies have shown that persistent invasive candidia-
sis is associated with an increased risk of mortality,13,14 others
have found no such association.11,12 The lack of a uniﬁed deﬁnition
of persistent candidemia, which is a major obstacle in assessing the
prevalence and the clinical relevance of persistent candidemia,
may explain the conﬂicting results of these studies. In this context,ses. Published by Elsevier Ltd. All rights reserved.
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Kuwait where 22% of neonates with Candida blood stream
infections die despite appropriate treatment. We aimed to
determine the rate of persistent candidemia and to describe the
clinical importance and the risk factors of persistent candidemia
over a period of 4 years in Kuwait.
2. Materials and methods
We performed a retrospective chart review of infants admitted
to the Neonatal Care Unit of the Maternity Hospital in Kuwait
between January 2007 and December 2010 who had a peripheral
blood culture positive for Candida. Persistent candidemia was
deﬁned as the isolation of the same Candida species more than 6
days after the date on which antifungal therapy was initiated, or
death due to Candida infection within 6 days of antifungal
treatment. Non-persistent candidemia was deﬁned in those who
had sterile blood cultures within 6 days of initiation of antifungal
treatment.
We followed the standard treatment protocol in treating these
cases, which included amphotericin B (1.5 mg/kg/day), or lipo-
somal amphotericin B for neonates with renal impairment (5–
7.5 mg/kg/day), as the ﬁrst-line treatment. Either ﬂuconazole
(12 mg/kg loading dose, then 6 mg/kg/day) or caspofungin (2 mg/
kg) was sequentially added if cultures from either blood or
cerebrospinal ﬂuid (CSF) remained positive despite 5 days of
therapy. Any indwelling central catheter was immediately
removed from the affected infant once the diagnosis of candidemia
was established. In order to reduce the incidence of invasive fungal
infections, prophylactic low-dose ﬂuconazole (3 mg/kg/day) was
given to every low birth weight (LBW) infant (<1500 g) for 14 days
starting at 7 days after birth.
Follow-up of infants with Candida infections comprised
cultures of blood every 72 h until a minimum of two negative
cultures were obtained. Other culture sites included the central
line tip (when removed), urine, endotracheal tube (ETT) tip (when
changed or removed), and ETT secretions in ventilated babies. An
ophthalmologic examination for fungal ophthalmitis and imaging
studies such as renal ultrasound and echocardiography were
routinely performed and repeated weekly in the case of a
persistent infection. Complete blood counts and blood urea
nitrogen, serum creatinine, and liver enzyme assessments were
routinely performed for infants on antifungal treatment.
The isolation and identiﬁcation of yeasts was performed using a
BACTEC 9240 system (Becton Dickinson, Paramus, NJ, USA), using
BACTEC Peds Plus/F culture vials. All positive cultures were Gram-
stained and subcultures were made on blood agar, chocolate agar,
and MacConkey agar. Yeast pathogens were subcultured on
Sabouraud dextrose agar. A germ tube test was performed for
the presumptive identiﬁcation of C. albicans. All the yeast isolates
were processed for identiﬁcation to the species level using a Vitek
yeast identiﬁcation system (bioMe´rieux, France).
Isolates were tested for antifungal susceptibility to amphoteri-
cin B and ﬂuconazole by Etest (AB Biodisk, Solna, Sweden) on RPMI
1640 agar supplemented with 2% glucose. The test was performed
in accordance with the method recommended by the manufactur-
er. The plates were incubated at 35 8C and minimum inhibitory
concentrations (MICs) were read after 24–48 h of incubation. The
point at which inhibition ellipses intercepted the scale on the
antifungal strip was taken as the MIC for each test isolate.
Interpretive susceptibility breakpoints for ﬂuconazole were those
recommended by the Clinical and Laboratory Standards Institute
(CLSI).15 Because of the lack of deﬁned breakpoints for amphoteri-
cin B, an isolate showing a MIC of 1.0 mg/ml was considered as
susceptible and those with a MIC >1 mg/ml were considered
resistant.16Data on demographic variables and associated risk factors such
as gestational age, birth weight and therapeutic outcome were
extracted from the clinical records using a standard form. Data on
the clinical and microbiological outcomes, including focal com-
plications, in addition to details of the antifungal drugs used
(dosing regimen and duration) were collated. Data were entered
and analyzed using SPSS software. The Chi-squared test was used
where applicable to test the differences in categorical data,
otherwise Fisher’s exact test was used. The Mann–Whitney U-test
was used to investigate the differences in continuous variables
between infants with persistent candidemia and infants with non-
persistent candidemia. Stepwise logistic regression was used to
identify the independent factors associated with persistent
candidemia. This analysis included sex, gestational age, birth
weight, ﬂuconazole prophylaxis, presence of a CVC, platelet count
<50  109/l, and previous or concomitant necrotizing enterocolitis
(NEC). The analysis was done twice, with gestational age and birth
weight ﬁtted either as continuous or as categorical indicator
variables using clinically acceptable cutoff points. The study was
approved by the Joint Ethics Committee of Kuwait University and
the Ministry of Health.
3. Results
During the study period, a total of 92 infants with Candida
infection were identiﬁed. Three infants with Candida infection
were excluded as they died before the initiation of antifungal
treatment. The analysis was carried out on the remaining 89
infants who were divided into two groups according to the time of
blood sterilization, i.e., those with persistent and those with non-
persistent candidemia. Of the 89 cases of Candida infection, 54
(60.7%, 95% conﬁdence interval (CI) 49.7–70.9%) met the deﬁnition
of persistent infection (i.e., isolation of the same Candida species
more than 6 days after the start of antifungal treatment, or death
within 6 days of antifungal treatment). Only ﬁve neonates died
within 6 days of antifungal therapy, three of whom died after 5
days. Excluding these ﬁve neonates did not change the incidence of
persistent candidemia materially (n = 49, 58.3%; 95% CI 47.1–
69.0%). Demographic and maternal characteristics of the infants
with persistent and non-persistent candidemia are shown in
Table 1. Infants with persistent candidemia were more likely to be
female and have a lower birth weight than those with non-
persistent candidemia. There was no signiﬁcant difference
between infants with persistent and non-persistent candidemia
with regard to the mode of delivery or the age at which the Candida
infection started.
Table 2 shows the distribution of the main risk factors for
Candida infection in infants with persistent and non-persistent
candidemia. Infants with persistent candidemia were more likely
to have a CVC at the time of diagnosis or to have had ﬂuconazole
prophylaxis or undergone surgery. Other risk factors such as the
use of broad-spectrum antibiotics and the presence of an ETT were
slightly more common in infants with persistent candidemia
compared to infants with non-persistent candidemia, although the
differences were not statistically signiﬁcant. With the exception of
two infants, all were on total parenteral nutrition (TPN), and there
was no difference in the duration of TPN between infants with
persistent candidemia and those with non-persistent candidemia.
Only two infants with non-persistent candidemia received
corticosteroids (data not shown).
Table 3 shows the distribution of the different Candida species,
MICs of the drugs used, and some laboratory indicators, in addition
to the case-fatality rate, in the infants with persistent and non-
persistent candidemia. C. albicans was the most prevalent species
in non-persistent candidemia, while C. parapsilosis was more
common among infants with persistent candidemia. No signiﬁcant
Table 1
Demographic and maternal characteristics of neonates with persistent and non-persistent Candida infections
Characteristic Persistent candidemiaa p-Value
Yes (n = 54), n (%) No (n = 35), n (%)
Gender, male 25 (46.3) 24 (68.6) 0.04
Born in the hospital, yes 47 (87.0) 30 (85.7) 0.86
Multiple pregnancy, yes 23 (42.6) 9 (25.7) 0.10
Mode of delivery, normal delivery 21 (38.9) 11 (31.4) 0.47
Intrapartum use of antibiotics 31 (57.4) 14 (40.0) 0.11
Gestational age, median (IQR) weeks 28 (25–30) 28 (27–31) 0.04
24–28 weeks 34 (63.0) 18 (51.4) 0.53
29–33 weeks 14 (25.9) 11 (31.4)
34 weeks 6 (11.1) 6 (17.14)
Birth weight, median (IQR) g 970 (720–1320) 1130 (940–1400) 0.04
1000 g 32 (59.3) 12 (34.3) 0.05
1001–1500 g 13 (24.1) 16 (45.7)
1501 g 9 (16.7) 7 (20.0)
Age at onset, median (IQR) days 17.5 (12–25) 18 (11–27) 0.97
<7 days 3 (5.6) 3 (8.6) 0.68
7 days 51 (94.4) 32 (91.4)
IQR, interquartile range.
a Deﬁned as a positive blood culture more than 6 days after the initiation of treatment, or death due to Candida within 6 days of treatment; amphotericin B (1.5 mg/kg/day)
or liposomal amphotericin B (5–7.5 mg/kg/day) was used as ﬁrst-line treatment and ﬂuconazole (12 mg/kg loading dose, then 6 mg/kg/day) or caspofungin (2 mg/kg) as
second-line treatment.
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MICs for amphotericin B and ﬂuconazole. More than half of the
infants with persistent candidemia died from the infection, while
only one infant with non-persistent candidemia died (p < 0.001).
Another infant with persistent candidemia and two infants with
non-persistent candidemia died from causes unrelated to the
infection.
Backwards and forwards selection using stepwise logistic
regression identiﬁed three independent factors associated with
persistent candidemia. These were female gender (odds ratio (OR)
2.91, 95% CI 1.07–7.88; p = 0.04), the presence of a CVC at diagnosis
(OR 3.68, 95% CI 1.24–10.90; p = 0.02), and a platelet count
<50  109/l (OR 5.24, 95% CI 1.89–14.49; p = 0.001).
Despite a careful search for disseminated Candida infection,
there was no clinical or radiological evidence of endocarditis,
osteomyelitis, endophthalmitis, or liver or splenic abscesses. There
was also no evidence of central nervous system (CNS) abscess,
although the CSF was positive in seven cases, all with persistent
candidemia. There was also no evidence of cutaneous abscess or
renal abscess although the urine was positive in four cases, two of
whom had a persistent infection.Table 2
Distribution of the main risk factors for Candida infection in infants with persistent an
Variable Persistent
Yes (n = 5
Fluconazole prophylaxis, yes 25 (46.3)
Prior use of broad-spectrum antibiotics, yes 40 (74.1)
Presence of a central catheter at diagnosis, yes 44 (81.5)
Duration of the central catheter, median (IQR) days 14 (10–21
Presence of an endotracheal tube, yes 49 (90.7)
Duration of endotracheal tube, median (IQR) days 22 (14–3
Duration of total parenteral nutrition 21.5 (15–
Previous or concomitant NEC 29 (53.7)
Surgery, yes 6 (11.1)
Blood glucose at diagnosis
Low 16 (29.6)
Normal 22 (40.7)
High 16 (29.6)
IQR, interquartile range; NEC, necrotizing enterocolitis.
a Deﬁned as a positive blood culture more than 6 days after the initiation of treatment,
or liposomal amphotericin B (5–7.5 mg/kg/day) was used as ﬁrst-line treatment and ﬂ
second-line treatment.4. Discussion
The prevalence and the clinical importance of persistent
candidemia have attracted considerable attention in recent
years.14,17 We conducted a 4-year study to review the prevalence
and the clinical relevance of persistent Candida bloodstream
infections in our setting, one in which Candida infections
contribute to a large number of neonatal sepsis cases, with an
extremely high case-fatality rate despite systemic antifungal
therapy.4,5 Using a stringent deﬁnition of persistent candidemia
(isolation of the same Candida species more than 6 days after
starting antifungal therapy), our ﬁndings suggest that 60% of
neonatal bloodstream Candida infections are persistent and that
the majority of these cases have a poor clinical outcome. The
incidence of persistent candidemia in our study is similar to that
reported from other settings – 52% of Candida infections were
persistent beyond 5 days of infection in one study11 – but higher
than that reported recently from the USA where only nine out of
37 Candida infections were persistent.12 However, because of the
lack of a uniform deﬁnition of persistent candidemia, which is a
major obstacle in the assessment of its incidence and clinicald non-persistent candidemia
 candidemiaa p-Value
4), n (%) No (n = 35), n (%)
 8 (22.9) 0.02
 20 (57.1) 0.10
 21 (60.0) 0.03
.5) 11 (8–14) 0.08
 28 (80.0) 0.15
7) 13 (5–31) 0.05
40) 23 (16–35) 0.85
 11 (31.4) 0.04
 0 (0.0) 0.04
 11 (31.4) 0.4
 18 (51.4)
 6 (17.1)
 or death due to Candida within 6 days of treatment; amphotericin B (1.5 mg/kg/day)
uconazole (12 mg/kg loading dose, then 6 mg/kg/day) or caspofungin (2 mg/kg) as
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studies may not be appropriate.
Although persistent candidemia may indicate treatment failure,
it is known that Candida species take some time to clear from the
bloodstream even when the treatment is effective. Thus it is
essential to decide if a persistent positive culture is part of the
natural history of candidemia in a responding patient, or if it
represents a treatment failure.17 It has been suggested that
intrinsic drug resistance is rare and thus unlikely to play an
important role in treatment failure; this has been substantiated by
the lack of an obvious correlation between MICs and clinical
outcome.18 Consistent with other studies that have shown
resistance among Candida isolates causing bloodstream infections
to be low,18–21 all cultured yeast species from our patients were
found to be susceptible to the antifungal therapy and MICs were
not signiﬁcantly different between infants with persistent and
non-persistent candidemia (Table 3). Less than half of the Candida
infections were due to C. albicans, which supports previous reports
showing the causative agent to be shifting to non-albicans Candida
species, particularly C. parapsilosis.22,23 Also similar to other
studies,14 a signiﬁcantly higher frequency of C. parapsilosis was
found among infants with persistent candidemia compared to
infants with non-persistent candidemia. A recent literature review
showed higher persistent candidemia among patients treated with
ﬂuconazole in comparison to other antifungal agents.17 In our
setting, all infants received amphotericin B as the ﬁrst-line
treatment, and ﬂuconazole or caspofungin were only added in
the case of no response.
Authors have emphasized the importance of host-related
factors in the failure of antifungal therapy,17,18 one of which is
the immature immune system of VLBW infants, which may lead to
an inability to eliminate the fungus even though its growth has
been inhibited.7,11 In our setting, birth weight was signiﬁcantly
associated with persistent candidemia in the univariate analysis,
while other factors such as the presence of a central catheter and a
low platelet count were both signiﬁcantly associated with
persistent candidemia in the univariate and multivariate analyses.
Other studies have failed to demonstrate a relationship between
these factors and persistent candidemia in neonates,11,12,24
probably because of the lack of statistical power. Other factors
such as prior antibiotic therapy and the use of an ETT were also
more common among neonates with persistent compared to non-
persistent candidemia. Although not statistically signiﬁcant, these
ﬁndings are similar to those of a previous study which showed thatTable 3
Candida species, minimum inhibitory concentrations (MIC), and outcome of the infecti
Variable Persistent candidem
Yes (n = 54), n (%) 
Candida species 
C. albicans 24 (44.4) 
C. parapsilosis 26 (48.2) 
Other species 4 (7.4)b
Amphotericin B MIC, median (IQR) mg/ml 0.032 (0.016–0.04
Fluconazole MIC, median (IQR) mg/ml 0.5 (0.19–0.75) 
CSF positive 7 (13.0) 
Urine positive 2 (3.7) 
Rectal swab positive 4 (7.4) 
Platelet count at diagnosis <50  109/l 40 (74.1) 
Case-fatality 29 (54) 
CSF, cerebrospinal ﬂuid; IQR, interquartile range; MIC, minimum inhibitory concentrat
a Deﬁned as a positive blood culture more than 6 days after the initiation of treatment, 
or liposomal amphotericin B (5–7.5 mg/kg/day) was used as ﬁrst-line treatment and ﬂ
second-line treatment.
b Two C. glabrata, one C. guilliermondii, and one C. lusitaniae.
c Four C. famata, four C. glabrata, and one C. lusitaniae.the duration of preceding antibiotic use was signiﬁcantly higher
among infants with refractory candidemia.14 A low dosage and
hence a low serum level of antifungal drugs,25 or late initiation of
treatment,12 are further potential risk factors for persistent
candidemia in neonates. Also, it has been suggested that the
clearance of antifungal drugs is higher in children compared to
adults.18 In our unit, infants receive empiric antifungal therapy
immediately a fungal infection is clinically suspected; after 6 days
of treatment it is unlikely that a low serum level of antifungal drug
or late treatment are plausible explanations for the high rate of
persistent candidemia or its poor clinical outcome. A low
concentration of the drug at the site of infection such as the
CNS is another potential explanation in our setting, although only
seven neonates with persistent candidemia had a positive CSF.
The clinical importance of persistent candidemia is obvious in
our setting, as more than half of the neonates with persistent
candidemia died in comparison to only 3% of neonates with non-
persistent candidemia. This is in contrast to the ﬁndings of other
studies which have not found persistent candidemia to be
associated with a higher mortality,11,12 although one of these
studies showed an increased risk of endocarditis in neonates with
persistent candidemia.11 Both studies had a small number of
deaths and thus may have lacked statistical power. Our ﬁndings are
consistent with those of another study which reported higher
mortality in infants with invasive persistent candidiasis after 48 h
of treatment with both amphotericin B and ﬂuconazole.14 They are
also consistent with an earlier study which reported a higher
mortality among neonates with persistent invasive Candida
infections at more than 24 h after reaching target doses of
amphotericin B and ﬂuconazole.13 The distinction between
persistent candidemia before and after the start of antifungal
treatment is important, as persistent positive blood cultures
without treatment is somehow expected.17 Our deﬁnition of
persistent candidemia was more consistent with the latter studies,
which took into account the time at which the treatment started or
the time at which target levels of antifungal agents were
reached.13,14 Thus the evidence from our study and these two
studies suggests that persistent candidemia correlates with
mortality when it reﬂects a treatment failure. It has been argued
that obtaining blood cultures from those who are clinically
deteriorating, or those with a severe illness or with comorbidities,
may result in overestimation of the clinical relevance of the
persistent candidemia.17 The clinical relevance of persistent
candidemia in our study remained signiﬁcant after taking intoon in persistent and non-persistent candidemia
iaa p-Value
No (n = 35), n (%)
0.01
18 (51.4)
8 (22.9)
9 (25.7)c
7) 0.032 (0.016–0.064) 0.23
0.75 (0.25–1.5) 0.14
0 (0.0) 0.04
2 (5.7) 0.64
3 (8.6) 1.0
15 (42.9) 0.01
1 (3) <0.001
ion.
or death due to Candida within 6 days of treatment; amphotericin B (1.5 mg/kg/day)
uconazole (12 mg/kg loading dose, then 6 mg/kg/day) or caspofungin (2 mg/kg) as
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those who died of the Candida infection within 6 days of treatment
(ﬁve neonates died within 6 days of antifungal treatment).
Similar to other studies that have failed to identify an apparent
source of the candidemia in the majority of cases,11 the catheter tip
was positive in only three cases (two of whom had persistent
candidemia). Urine was positive in only four cases (two persistent
and two non-persistent candidemia) and rectal swabs were
positive in seven cases (four persistent and three non-persistent
candidemia). Despite a careful search for dissemination to other
organs using weekly CSF examinations, echocardiography, head
ultrasound, eye examinations, and abdominal imaging of the liver
and kidney, and bone scans if clinically indicated, no other sites of
infection were detected. CSF was positive in only seven cases, all
with persistent candidemia. Nevertheless, it has been suggested
that occult foci such as infected blood clots may escape detection
by the usual imaging methods and continue to serve as hidden nidi
for gradual replication and dissemination of the yeast.11,13,18
The limitations of this study include the difﬁculty in
generalizing the ﬁndings from a single centre to other settings.
We have investigated the susceptibility of Candida species from the
ﬁrst positive blood culture, but it is possible that resistance
developed while the patient was receiving antifungal agents.18
Autopsies were not conducted to verify that persistent candidemia
was the main cause of death. Although we have reported the
ﬁndings of a larger dataset compared to previous studies, issues
related to its retrospective design are important constraints in our
study and highlight the need for a prospective study.
In conclusion, our ﬁndings suggest that more than half of the
Candida infections among neonates in our setting are persistent
and this results in a high mortality. Drug resistance seems to be an
unlikely explanation for this high rate of persistent candidemia and
for its poor clinical outcome. Instead, host-related factors are
important determinants of the outcome in persistent candidemia.
These factors could be used to identify those at risk in order to
institute intensive preventive and treatment measures.
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